Skip to main content
See every side of every news story
Published • loading... • Updated

Sellas’ Cancer Vaccine Extends Survival in Blood Cancer Trial

The vaccine cut the risk of death by 41% and extended median overall survival to 24.0 months, the company said.

  • On Tuesday, SELLAS Life Sciences Group, Inc. announced positive topline results from the pivotal Phase 3 REGAL trial evaluating galinpepimut-S in patients with acute myeloid leukemia .
  • The REGAL trial evaluated GPS as maintenance monotherapy in 126 patients with AML who achieved a second or later complete remission and were ineligible for allogeneic stem cell transplantation.
  • GPS demonstrated a 41% reduction in the risk of death, with median overall survival of 24.0 months versus 14.7 months for patients receiving best available treatment.
  • SELLAS plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy, advancing preparations for a Biologics License Application submission in the first half of 2027.
  • Calling the data a "defining milestone," Angelos Stergiou, President and Chief Executive Officer of SELLAS, said the trial validates the company's WT1-targeted immunotherapeutic technology.
Insights by Ground AI

13 Articles

ReutersReuters
Reposted by
WTVBWTVB
Center

Sellas' vaccine extends survival in blood cancer trial

·London, United Kingdom
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 80% of the sources are Center
80% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Globe Newswire broke the news on Tuesday, November 17, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal